首页 | 本学科首页   官方微博 | 高级检索  
检索        

阿托伐他汀联合吡格列酮对大鼠缺血再灌注心肌的保护作用
引用本文:祖玉刚,陈还珍.阿托伐他汀联合吡格列酮对大鼠缺血再灌注心肌的保护作用[J].中国现代医生,2011,49(36):4-5,33.
作者姓名:祖玉刚  陈还珍
作者单位:山西医科大学第一临床医院心血管内科,山西太原,030001
摘    要:目的探讨阿托伐他汀、吡格列酮及二者联用预处理大鼠后,对缺血再灌注(I/R)心肌的保护作用,并探讨其可能的机制。方法选雄性健康Sprague—Dawley(SD)大鼠40只,将上述大鼠随机分为5组:假手术组(生理盐水,2mL/d,8例)、I/R组(生理盐水,2mL/d,8例)、阿托伐他汀组【阿托伐他汀,20mg/(kg·d),8例]、吡格列酮组【吡格列酮,3mg/(kg·d),8例】、阿托伐他汀+吡格列酮组【阿托伐他汀,20mg/(kg·d)+吡格列酮3mg/(kg·d),8例]。灌胃1周后,第8天制作大鼠在体心肌I/R模型。缺血30min,再灌注1h后测定血清丙二醛(MDA)及超氧化物歧化酶(SOD);Evansblue、TYC双重染色后,用图像分析软件计算梗死面积。结果阿托伐他汀组、吡格列酮组、阿托伐他汀+吡格列酮组与I/R组比较,心肌梗死面积减少,SOD升高、MDA降低(P〈0.01)。联合用药组较单独用药组心肌梗死面积减少,SOD升高,MDA降低(P〈0.01);较假手术组SOD降低,MDA升高(P〈0.01)。阿托伐他汀组与吡格列酮组各指标水平接近(P〉0.05)。结论阿托伐他汀、吡格列酮能减轻心肌缺血再灌注损伤,两药联合应用作用更加明显,其作用机制与提高血清SOD活性,降低MDA含量有关。

关 键 词:冠心病  阿托伐他汀  吡格列酮  心肌缺血再灌注  保护作用

Protective Effect of Atorvastatin and Pioglitazone on Ischemia and Reperfusion Myocardium in Rats
Authors:ZU Yugang  CHEN Huanzhen
Institution:Department of Cardiology,the First Hospital of Shanxi Medical University,Taiyuan 030001,China
Abstract:Objective To investigate atorvastatin,pioglitazone and two drugs in combination on ischemia-reperfusion myocardial pro- tective effects and the possible mechanism. Methods All 40 healthy SD rats were randomly divided into 5 groups:sham operation group (n=8,0.9%sodium chloride injection liquid,2mL/d),I/R group (n=8,0.9% sodium chloride injection liquid,2mL/d),atorvastatin group(n=8, atorvastatin, 20mg/kg· d)], pioglitazone groupn=8, pioglitazone 3mg/(kg ·d)],atorvastatin + pioglitazone groupn=8, atorvastat in, 20mg/(kg·d)+pioglitazone 3mg/(kg·d)].After one week garage make the rat model of myocardial ischemia-reperfusion in eight days,is chemia 30minute, one hour after reperfusion serum malondialdehyde (MDA) and superoxide dismutase ( SOD ).Evans blue, Trc double staining,using image analysis software to calculate infarct size. Results The atorvastatin group,pioglitazone group,atorvastatin + pioglita zone group and I/R group,infarct size reduction,SOD increased,MDA decreased(P〈0.01 ).Atorvastatin + pioglitazone group than in the atorvastatin group,pioglitazone group myocardial infarct size reduction,SOD increased,MDA decreased(P〈0.01 ).Compared with the sham group SOD decreased,MDA increased(P《0.01 ). Atorvastatin group and pioglitazone group close to the target level(P〉0.05). Conclu- sion Atorvastatin, pioglitazone can reduce myocardial ischemia-reperfusion injury,its role in combination of two drugs is more obvious. The mechanism is mediated by increasing SOD activity and decreasing MDA.
Keywords:Coronary heart disease  Atorvastatin  Pioglitazone  Myocardial ischemia-reperfusion  Protective effect
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号